U.S. Markets closed

Synthetic Biologics initiates development of monoclonal antibodies

Synthetic Biologics announced that it has initiated efforts to develop a monoclonal antibody therapy for the treatment of acinetobacter infections. Many strains of Acinetobacter are multidrug-resistant and pose an increasing global threat to hospitalized patients, wounded military personnel and those affected by natural disasters.